(Q42981999)

English

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

scientific article published on November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Chen-Hua Liu

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Chun-Jen Liu

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Chih-Lin Lin

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Cheng-Chao Liang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Shih-Jer Hsu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sheng-Shun Yang

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ching-Sheng Hsu

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Tai-Chung Tseng

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Chia-Chi Wang

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ming-Yang Lai

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jun-Herng Chen

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Pei-Jer Chen

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ding-Shinn Chen

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

0 references

publication date

1 November 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Clinical Infectious Diseases

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

47

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1260-1269

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Differences in treatment outcome for hepatitis C among ethnic groups.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

1 reference

https://api.crossref.org/works/10.1086%2F592579

21 January 2018

Identifiers

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

release_ylzpso6aircvdm6z66t5gyfrfq

1 reference

https://api.fatcat.wiki/v0/release/ylzpso6aircvdm6z66t5gyfrfq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18834319%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981999&oldid=1838428048"